Overview

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

Status:
Recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

The goal of the study is to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial infarction (STEMI)

Phase:

Phase 2

Details

Lead Sponsor:

R-Pharm Overseas, Inc.

Collaborators:

Cromos Pharma LLC
Cromos Pharma, LLC
DM 365, LLC
Keystat, LLC